Skip to main content
Year archive

NEUREN PHARMACEUTICALS LIMITED — 2021 filings

All 60 regulatory filings released by NEUREN PHARMACEUTICALS LIMITED (NEU) in 2021, sourced directly from the official regulator.

60 Filings
2021 Period
2021 filings (60)
Filing Released Lang
Becoming a substantial holder 8 pages 206.1KB
Major Shareholding Notification
2021-12-09 English
Positive topline results from Phase 3 trial in Rett syndrome 5 pages 175.2KB
Capital/Financing Update
2021-12-06 English
Neuren presenting at Bell Potter Healthcare Conference 18 pages 530.5KB
Investor Presentation
2021-11-09 English
Q3 2021 quarterly activity and cash flow report 9 pages 234.0KB
Interim / Quarterly Report
2021-10-27 English
Neuren receives feedback on IND for Phelan-McDermid syndrome 2 pages 153.5KB
Regulatory Filings
2021-10-20 English
Change of Director's Interest Notice - D Angus 2 pages 73.7KB
Director's Dealing
2021-10-19 English
US patent to 2034 granted for Neuren's NNZ-2591 in autism 2 pages 153.3KB
Regulatory Filings
2021-10-10 English
Application for quotation of securities - NEU 6 pages 27.3KB
Share Issue/Capital Change
2021-10-07 English
Change of Director's Interest Notice - P Davies 2 pages 99.9KB
Director's Dealing
2021-10-07 English
Change of Director's Interest Notice - J Pilcher 2 pages 100.2KB
Director's Dealing
2021-10-07 English
Change of Director's Interest Notice - J Harry 2 pages 99.9KB
Director's Dealing
2021-10-07 English
$3.3 million raised from oversubscribed SPP 2 pages 130.3KB
Capital/Financing Update
2021-10-05 English
Update - Proposed issue of securities - NEU 10 pages 38.5KB
Capital/Financing Update
2021-10-05 English
Feedback on Angelman IND and submission of Pitt Hopkins IND 2 pages 155.0KB
Capital/Financing Update
2021-09-30 English
IND application submitted for NNZ-2591 in Phelan-McDermid 2 pages 155.9KB
Regulatory Filings
2021-09-20 English
Share Purchase Plan Offer Booklet 11 pages 226.1KB
Capital/Financing Update
2021-09-16 English
Application for quotation of securities - NEU 6 pages 27.7KB
Share Issue/Capital Change
2021-09-15 English
New patent issued to 2032 for Neuren's trofinetide in Brazil 2 pages 160.5KB
Regulatory Filings
2021-09-15 English
Section 708A Notice 1 page 287.1KB
Capital/Financing Update
2021-09-15 English
Placement to accelerate NNZ-2591 across 4 indications 4 pages 185.8KB
Capital/Financing Update
2021-09-12 English
Proposed issue of securities - NEU 10 pages 38.6KB
Capital/Financing Update
2021-09-12 English
Investor Presentation, 13 September 2021 47 pages 1.6MB
Investor Presentation
2021-09-12 English
Notification of investor presentation, 9.00 AEST 13 Sept 21 1
Investor Presentation
2021-09-09 English
Trading Halt 2 pages 125.2KB
Capital/Financing Update
2021-09-08 English
FDA grants Orphan Drug designation for Prader-Willi syndrome 2 pages 157.3KB
Regulatory Filings
2021-09-02 English
Trofinetide Rett syndrome clinical trial in girls aged 2-5 3 pages 179.5KB
Regulatory Filings
2021-08-31 English
Angelman IND and Ethics applications submitted for NNZ-2591 2 pages 155.2KB
Regulatory Filings
2021-08-31 English
R&D Tax Incentive Advance Overseas Finding Approval 2 pages 156.1KB
Capital/Financing Update
2021-08-29 English
Half Yearly Report and Accounts 12 pages 356.4KB
Interim / Quarterly Report
2021-08-24 English
Half-year shareholder update 4 pages 205.7KB
Interim / Quarterly Report
2021-08-24 English
Notification of investor webinar 1 page 150.9KB
Investor Presentation
2021-08-16 English
Phase 3 enrolment successfully completed, results in Q4 2021 3 pages 221.9KB
Capital/Financing Update
2021-08-04 English
Q2 2021 quarterly activity and cash flow report 9 pages 283.1KB
Interim / Quarterly Report
2021-07-29 English
Change of Director's Interest Notice 2 pages 74.1KB
Director's Dealing
2021-06-27 English
AGM Chairman's Address and CEO Presentation 24 pages 750.3KB
AGM Information
2021-06-21 English
Results of Meeting 1 page 62.4KB
Declaration of Voting Results & Voting Rights Announcements
2021-06-21 English
Change of Director's Interest Notice 2 pages 100.2KB
Director's Dealing
2021-06-15 English
Neuren CEO Jon Pilcher appointed to board of directors 2 pages 151.0KB
Board/Management Information
2021-06-14 English
Initial Director's Interest Notice 2 pages 67.4KB
Director's Dealing
2021-06-14 English
Investor presentation, 15 June 2021 31 pages 884.9KB
Investor Presentation
2021-06-14 English
Update - Annual General Meeting 2021 2 pages 153.1KB
AGM Information
2021-06-09 English
Neuren to present at MST Access investor conference 1
Investor Presentation
2021-06-09 English
Positive FDA meetings enable INDs for three Phase 2 trials 3 pages 155.1KB
Regulatory Filings
2021-05-31 English
Notice of Annual General Meeting/Proxy Form 11 pages 292.8KB
AGM Information
2021-05-20 English
Virtual AGM online guide 4 pages 1.8MB
AGM Information
2021-05-20 English
New patent issued to 2032 for Neuren's trofinetide in Canada 2 pages 160.9KB
Regulatory Filings
2021-04-28 English
Annual Report to shareholders 58 pages 1.9MB
Annual Report
2021-04-26 English
Appendix 4G 14 pages 169.6KB
Regulatory Filings
2021-04-26 English
Quarterly report and cash flow statement for Q1 2021 9 pages 271.9KB
Interim / Quarterly Report
2021-04-21 English
Investor presentation, 23 March 2021 30 pages 877.1KB
Investor Presentation
2021-03-22 English
Neuren successfully completes manufacturing for Phase 2 2 pages 189.6KB
Capital/Financing Update
2021-03-09 English
Preliminary Final Report and 2020 full year accounts 30 pages 530.7KB
Annual Report
2021-02-23 English
Neuren approaching transforming milestones in 2021 4 pages 171.4KB
Annual Report
2021-02-23 English
Neuren corporate presentation, 24 February 2021 30 pages 881.4KB
Investor Presentation
2021-02-23 English
Change of Director's Interest Notice 2 pages 99.9KB
Director's Dealing
2021-02-17 English
Notification of investor briefing webinar 1 page 95
Investor Presentation
2021-02-16 English
Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline 5 pages 235.6KB
Capital/Financing Update
2021-02-15 English
Successful Phase 1 trial for Neuren's NNZ-2591 2 pages 159.8KB
Capital/Financing Update
2021-02-14 English
Quarterly report and cash flow statement for Q4 2020 8 pages 209.4KB
Interim / Quarterly Report
2021-01-28 English
European Commission grants 3 NNZ-2591 Orphan designations 2 pages 148.6KB
Regulatory Filings
2021-01-10 English